Mass Tort brief
Talc Settlement Framework and Medical Device MDLs Drive Mass Tort Landscape
Major corporate defendants face shifting liability as J&J proposes a $5.5B settlement while court rulings reopen cold medicine and catheter claims.
Mass Tort
J&J's $5.5 billion deal marks a pragmatic pivot away from bankruptcy maneuvers — setting up a massive payout that could finally end decades of talc litigation.
BackgroundJ&J faces tens of thousands of personal injury claims alleging long-term asbestos contamination in its baby powder caused cancer. The company previously attempted to resolve claims through controversial corporate bankruptcy filings that federal courts repeatedly struck down.
- The proposed settlement framework covers federal multidistrict litigation in New Jersey along with related state court actions, consolidating years of fragmented litigation across multiple jurisdictions.
- At least 95% of remaining claimants must sign onto the deal for it to take final legal effect, giving plaintiffs' firms significant collective leverage over final execution.
- The agreement followed court orders requiring plaintiffs to produce specific causation evidence in bellwether trials, forcing both sides toward a negotiated resolution rather than individual courtroom fights.
Mass Tort
Denying summary judgment forces Bard to face jury trials over catheter defects — escalating financial pressure toward a comprehensive multidistrict settlement.
BackgroundMultidistrict litigation against Bard alleges its silicone PowerPort catheter devices degrade internally, leading to fractures and life-threatening vascular injuries. Summary judgment rulings establish critical legal parameters and evidence standards for upcoming bellwether trials.
- The court found triable issues of fact regarding whether barium sulfate degradation caused catheter fractures, rejecting the defense's attempt to dismiss expert scientific testimony before trial.
- The judge rejected Bard's defense claiming the medical device was an unavoidably unsafe product under state law, holding manufacturers accountable for alleged design flaws.
- Claims for strict liability, failure to warn, and punitive damages remain intact for trial, exposing parent company Becton Dickinson to substantial financial penalties if juries side with plaintiffs.
Mass Tort
The Second Circuit ruling reopens major legal liability for brand-name drugmakers — setting up extensive consumer class actions over ineffective over-the-counter cold medicines.
BackgroundAn FDA advisory panel concluded in 2023 that oral phenylephrine is ineffective as a nasal decongestant, sparking nationwide consumer fraud litigation against drugmakers. A lower court previously dismissed all claims on federal preemption grounds.
- The appellate court affirmed preemption for generic monograph items but revived claims against brand-name drugs, creating distinct legal liabilities between generic and brand-name manufacturers.
- Judges ruled manufacturers could have updated efficacy labels under FDA regulations as scientific consensus shifted, rejecting arguments that FDA inaction shielded companies from consumer claims.
- The decision also held that indirect buyers can bring civil RICO claims against pharmaceutical distributors, opening broader civil litigation avenues beyond direct retail purchases.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.